Minerva Neurosciences, Inc.

NASDAQ:NERV

Biotechnology

Healthcare
$2.18 -6.49%

-$0.30 today

Market cap
$108.64M
Beta
-0.11
P/E (TTM)
-0.2
EPS (TTM)
-$8.46
52W Low $1.76High $12.46

Volume 0.28M

Average 0.21M

NERV Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Minerva Neurosciences, Inc.NASDAQ: NERV

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q2 FY2026 selling, general & admin of $3.45M rose 66.4% year over year, behind the +118480.6% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at -4.1% a year.

Context

  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +66.4% toward the trailing-twelve-month pace of +118480.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.45M-100.0% QoQ
Last fiscal yearDec 2025
$9.34M-6.1% YoY
LTMJun 2026
$11.42B+118480.6% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.4%——
1 year-6.1%——
3-year CAGR-4.1%——
5-year CAGR——
10-year CAGR——

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
9.34M USD
Year-over-year change
-6.1%
4-year CAGR
-8.5%

Selling, General & Admin vs competitors

How NERV compares with its peers on the latest reported figures

  • NERV's LTM Jun 2026 selling, general & admin of $11.42B is the highest of the 4 companies compared; the peer median is $10.38M.
  • Its year-over-year change of +118480.6% is the highest of 4, against a peer median of +5.1%.
  • Over three fiscal years its annual growth of -4.1% compares with a peer median of -5.3%.
NERV Competitors Peer median
Selling, General & Admin for NERV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$11.42B +118480.6%-4.1%—
RLYBRallybio CorporationLTM Mar 2026$16.24M -4.1%-19.2%1893.0%
NRXSNeurAxis, Inc.LTM Mar 2026$10.38M +5.1%+23.2%242.5%
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$5.69M +18.2%-5.3%—
Peer median (excluding NERV) $10.38M+5.1%-5.3%1067.8%

Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.04M14.65M12.71M11.9M5.76M
Selling, General & Admin13.33M10.58M10.41M9.95M9.34M
Operating Expenses45.37M25.23M23.12M21.85M15.1M
Depreciation & Amortization101.79K8.51K30.98K22.47K5.44K
EBITDA(45.28M)(24.69M)(21.69M)6.02M(293.42M)
EBITDA Margin—————
Operating Income(45.37M)(25.23M)(23.12M)(21.85M)(15.1M)
Operating Margin—————
Interest Income16.52K556.95K1.44M1.27M948.12K
Interest Expense6.33M7.41M8.28M4.56M0
Other Income / Expenses(6.34M)(6.88M)(6.89M)23.29M(278.32M)
Income Before Tax(51.71M)(32.11M)(30.01M)1.44M(293.42M)
Pre-Tax Margin—————
Income Tax Expense(1.8M)0000
Net Income(49.91M)(32.11M)(30.01M)1.44M(293.42M)
Net Margin—————
EPS (Basic)(9.35)(6.01)(4.61)0.19(34.67)
EPS (Diluted)(9.35)(6.01)(4.61)0.19(34.67)
Weighted Avg Shares5.34M5.34M6.51M7.57M8.46M
Weighted Avg Shares (Diluted)5.34M5.34M6.51M7.57M8.46M

Minerva Neurosciences, Inc.

NASDAQ:NERV

Intrinsic Alpha fair value

Locked

Current Price

$2.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.